Skip to content
Biotechnology

Lithuanian Biotech Pioneer ‘Nando’ Embarks on Global Expansion With New Management Team and Innovative Production Line

Nando 2 mins read

"Nando", a leading Lithuanian-owned biotechnology company known for its groundbreaking work in developing microbiological products for agriculture, that helped to save up to 50M on fertilisers, announces a significant bolstering of its management team and an ambitious expansion of its biotechnological production line. This move is set to position "Nando" not just as a leader in Lithuania but as a formidable player on the international stage.

KAUNAS, LITHUANIA / ACCESSWIRE / May 7, 2024 / In a strategic enhancement of its management team, "Nando" welcomes four seasoned professionals, each bringing a wealth of experience from reputable organizations. Gytis Kubilius, with a solid background in management at "SEB" and "Citadele" banks; Mindaugas Navickas, previously International Sales Manager at "Teltonika Networks"; Arūnas Jusas, former General Manager at "Timac AGRO"; and Giedrė Mockienė, who served as HR Manager at UAB "Yara", are now integral parts of "Nando's" leadership, aiming to spearhead ambitious development projects.

To cater to the surging demand for microbiological alternatives to mineral fertilizers and plant protection products, "Nando" has invested about €3 million in a unique biotechnology line. This investment boosts production volume, enhances productivity, and ensures competitive pricing to meet the escalating market demand. With a technology that is currently patent-pending, "Nando" exports to over 20 countries, including Great Britain, Ukraine, Estonia, Kazakhstan, Latvia, Poland, Romania and beyond.

Justinas Taruška, CEO of "Nando", stated, "Our main goal is to feature a highly automated biotechnological production line. This will not only elevate the agro-biotechnology sector's value in Lithuania but also accelerate sustainable and economically viable agricultural technologies across Europe and other continents." The new production line is renowned for its unique microorganism purification technology, a rarity in the entire Baltic region. It promises an efficient production of stable, high-yield microbiological products in powder form, a technology with limited competition.

The inclusion of new management members, with their extensive international experience, underscores "Nando's" commitment to employee development and its focus on penetrating foreign markets, including Europe, North and South America, Asian and Africa countries. This strategic move coincides with the launch of the new production line for microbiological products.

Founded in 2007, "Nando" stands at the forefront of the biotech industry, developing and manufacturing microbiological products and chemical additives for agriculture. With one of Northern Europe's leading R&D centers and partnerships with global research institutions, "Nando" has introduced over 50 innovative products, vital to the agro, livestock. Currently, the company is intensifying its export activities, with operations spanning over 20 countries in Europe, North and South America, Asian and Africa. The "Nando Group" proudly employs more than 50 professionals dedicated to advancing global biotechnology solutions.

Contact Information:

Milda Gauliene
Marketing specialist
milda@nando.lt
+37066475297

SOURCE: Nando

.

View the original press release on newswire.com.

More from this category

  • Biotechnology
  • 16/09/2024
  • 16:24
Magellan Stem Cells

Magellan Stem Cells welcomes $7m Australian Government grant

Magellan Stem Cells has welcomed a $7 million grant from the Australian Government’s Medical Research Future Fund (MRFF) to help fund a Phase III…

  • Contains:
  • Biotechnology, Business Company News
  • 12/09/2024
  • 09:55
Jane Morgan Management

BlinkLab (ASX:BB1) Signs Partnership with European INTER-PSY for Clinical Trial, Supporting US and EU Regulatory Approval and Future Market Adoption

Sydney, Australia – 12 September 2024 | BlinkLab Limited (ASX: BB1) (“BlinkLab” or “the Company”), an innovative digital healthcare company developing AI-powered sensory assessments on smartphones for detecting neurodevelopmental conditions, is pleased to announce a partnership with INTER-PSY in the Netherlands. The new partnership will facilitate a prospective clinical trial for the early diagnosis of autism in children aged 2-6 years old, aiding BlinkLab on its path to both US and European regulatory approval and eventual market adoption. Highlights: Clinical Trials with INTER-PSY: The partnership will see INTER-PSY conducting a study to evaluate the effectiveness of BlinkLab’s technology for aiding…

  • Contains:
  • Biotechnology
  • 06/09/2024
  • 12:00
Cleo Diagnostics Limited. ASX.COV

Cleo Commences U.S. Clinical Trials for its Ovarian Cancer Diagnostic Blood Test

Highlights U.S. clinical trials commenced with first patients enrolled over 8 recruitment centres Trial will validate the use ofCLEO’s ovarian cancer blood test for the U.S. market Pathway set toward FDA submission in CY2025. ___________ MELBOURNE, AUSTRALIA, 6 September 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test. Commencement of U.S. Clinical Trials CLEO’s pivotal FDA-enabling clinical trial has commenced in the United States, with first patients recruited into the study. The trial is designed to benchmarkCLEO’s technology, with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.